You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 16, 2025

Drug Price Trends for CEFADROXIL


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for CEFADROXIL

Average Pharmacy Cost for CEFADROXIL

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug NameNDCPrice/Unit ($)UnitDate
CEFADROXIL 500 MG/5 ML SUSP 68180-0182-03 0.22471 ML 2025-03-19
CEFADROXIL 1 GM TABLET 00093-4059-53 3.56151 EACH 2025-03-19
CEFADROXIL 250 MG/5 ML SUSP 16714-0389-01 0.18007 ML 2025-03-19
CEFADROXIL 250 MG/5 ML SUSP 65862-0083-01 0.18007 ML 2025-03-19
>Drug Name>NDC>Price/Unit ($)>Unit>Date
Showing 1 to 4 of 4 entries

Best Wholesale Price for CEFADROXIL

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug NameVendorNDCCountPrice ($)Price/Unit ($)UnitDatesPrice Type
CEFADROXIL 500MG CAP AvKare, LLC 00093-3196-01 100 50.60 0.50600 EACH 2023-06-15 - 2028-06-14 FSS
CEFADROXIL 500MG CAP AvKare, LLC 00093-3196-53 50 28.40 0.56800 EACH 2023-06-15 - 2028-06-14 FSS
>Drug Name>Vendor>NDC>Count>Price ($)>Price/Unit ($)>Unit>Dates>Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Showing 1 to 2 of 2 entries

Market Analysis and Price Projections for Cefadroxil

Market Size and Growth Projections

The global market for cefadroxil is experiencing steady growth, driven by several key factors. As of 2023, the market was valued at approximately USD 286 million to USD 330 million, depending on the source[1][2][3].

  • By 2030, the market is forecasted to reach USD 354.3 million, growing at a Compound Annual Growth Rate (CAGR) of 3.1% from 2024 to 2030[1].
  • Another projection indicates that the market will reach USD 430 million by 2031, with a CAGR of 3.5% from 2024 to 2031[2].
  • A longer-term forecast suggests the market will reach USD 0.43 billion by 2032, maintaining a CAGR of 3.50% during the forecast period of 2023 to 2032[3].

Market Drivers

Several factors are driving the growth of the cefadroxil market:

  • Increasing Incidence of Bacterial Infections: The rising prevalence of respiratory, urinary tract, and skin infections is a significant driver. Cefadroxil's broad-spectrum effectiveness makes it a preferred choice for treating these infections[2][3].
  • Growing Healthcare Access: Expanding healthcare infrastructure and increasing access to medications in developing countries are fueling the demand for antibiotics like cefadroxil[2][3].
  • Improvements in Pharmaceutical Production: Advances in production techniques have made cefadroxil more accessible and cost-effective, contributing to its market growth[2].
  • Clinical Preference: The growing awareness among medical professionals about the importance of effective antibiotic therapy supports the use of cefadroxil in clinical settings[2].

Market Segmentation

The cefadroxil market is segmented based on several criteria:

  • By Application: The market is segmented into various applications such as respiratory infections, skin infections, urinary tract infections, pharyngitis, and dental infections[2][3].
  • By Product: The market includes different product forms like capsules, tablets, powder for suspension, extended release, and chewable tablets[2][4].
  • By Geography: The market is divided into regions such as North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The Asia-Pacific region is experiencing the highest CAGR due to factors like increasing population, rising prevalence of bacterial infections, and improving healthcare infrastructure[3].

Competitive Landscape

The cefadroxil market is highly competitive, with several key players:

  • Leading Companies: Union Chempharma, NCPC, Qilu Antibiotics, Lupin Pharmaceuticals, Fukang, Dongying Pharmaceutical, Alkem, SALUBRIS, LIVZON, CSPC, Covalent Laboratories, LKPC, HPGC, and Huafangpharm are some of the major players in the market[1][4].
  • Strategic Initiatives: Companies are focusing on research and development to improve cefadroxil formulations, expand their market presence, and enhance their financial outlook[4].

Price Analysis

The prices of cefadroxil vary based on the form and quantity of the medication:

  • Oral Capsule: The cost for a 500 mg oral capsule can range from $2.03 to $20.30 for a supply of 10 capsules, depending on the pharmacy and any discounts applied[5].
  • Oral Powder for Reconstitution: The price for 100 milliliters of 250 mg/5 mL oral powder can start from $51.45, and for 75 milliliters of 500 mg/5 mL, it can start from $53.06[5].
  • Oral Tablet: A supply of 50 tablets of 1000 mg oral tablets can cost around $340.34[5].

Regional Market Dynamics

The Asia-Pacific region is the fastest-growing segment due to:

  • High Prevalence of Bacterial Infections: The region experiences a high incidence of bacterial infections, which drives the demand for effective antibiotics like cefadroxil.
  • Improving Healthcare Infrastructure: Expanding healthcare facilities and increasing awareness of healthcare contribute to the heightened demand for antibiotics in this region[3].

Challenges and Opportunities

While the market is growing, there are several challenges and opportunities to consider:

  • Antibiotic Resistance: The increasing concern over antibiotic resistance is a challenge that the market must address through continuous research and development of more effective formulations[2][3].
  • Regulatory Reforms: Changes in regulatory policies can impact the market, but these can also be turned into opportunities if assessed properly[4].

Key Takeaways

  • The global cefadroxil market is projected to grow significantly, driven by the increasing incidence of bacterial infections and improvements in healthcare access.
  • The market is segmented by application, product form, and geography, with the Asia-Pacific region showing the highest growth rate.
  • Key players are focusing on R&D to improve formulations and expand their market presence.
  • Prices vary based on the form and quantity of the medication, with discounts and patient assistance programs available.

Frequently Asked Questions (FAQs)

Q: What is the projected market size of cefadroxil by 2030? A: The market is forecasted to reach USD 354.3 million by 2030, growing at a CAGR of 3.1% from 2024 to 2030[1].

Q: What are the main drivers of the cefadroxil market? A: The main drivers include the increasing incidence of bacterial infections, growing healthcare access, improvements in pharmaceutical production, and clinical preference for effective antibiotic therapy[2][3].

Q: Which region is experiencing the highest growth rate in the cefadroxil market? A: The Asia-Pacific region is experiencing the highest growth rate due to factors such as a high prevalence of bacterial infections and improving healthcare infrastructure[3].

Q: What are the different forms of cefadroxil available in the market? A: Cefadroxil is available in various forms including capsules, tablets, powder for suspension, extended release, and chewable tablets[2][4].

Q: How can companies gain a competitive edge in the cefadroxil market? A: Companies can gain a competitive edge by focusing on research and development to improve formulations, expanding their market presence, and leveraging strategic initiatives such as partnerships and geographical expansions[4].

Sources:

  1. Valuates Reports: Global Cefadroxil Industry Research Report.
  2. Market Research Intellect: Cefadroxil Market Size, Share, Growth & Forecast.
  3. Market Research Future: Cefadroxil Market Trends, Growth, Forecast 2032.
  4. OpenPR: Cefadroxil Market: How can a player gain a competitive edge?
  5. Drugs.com: Cefadroxil Prices, Coupons, Copay Cards & Patient Assistance.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.